Welcome to LookChem.com Sign In|Join Free

CAS

  • or

52023-68-4

Post Buying Request

52023-68-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

52023-68-4 Usage

Uses

5-Amino-2-(4-morpholinyl)pyridine is used as pharmaceutical intermediate.

Check Digit Verification of cas no

The CAS Registry Mumber 52023-68-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,0,2 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 52023-68:
(7*5)+(6*2)+(5*0)+(4*2)+(3*3)+(2*6)+(1*8)=84
84 % 10 = 4
So 52023-68-4 is a valid CAS Registry Number.
InChI:InChI=1/C9H13N3O/c10-8-1-2-9(11-7-8)12-3-5-13-6-4-12/h1-2,7H,3-6,10H2/p+1

52023-68-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H50699)  5-Amino-2-(4-morpholinyl)pyridine, 97%   

  • 52023-68-4

  • 250mg

  • 701.0CNY

  • Detail
  • Alfa Aesar

  • (H50699)  5-Amino-2-(4-morpholinyl)pyridine, 97%   

  • 52023-68-4

  • 1g

  • 2527.0CNY

  • Detail

52023-68-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-Morpholinopyridin-3-amine

1.2 Other means of identification

Product number -
Other names 6-morpholin-4-ylpyridin-3-amine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:52023-68-4 SDS

52023-68-4Relevant articles and documents

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

-

Page/Page column 132-133, (2021/02/12)

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

-

Paragraph 0207; 0234, (2021/04/02)

The present disclosure relates to a class of fused pyrimidine compounds of Formula I, their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to a process of preparation of these fused pyrimidine compounds, and to pharmaceutical compositions containing them.

C-TERMINAL SRC KINASE INHIBITORS

-

Paragraph 147; 148, (2020/07/14)

Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response in a subject in need thereof. (G)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 52023-68-4